|
Dallas–Fort Worth, TX Press Releases
|
(Dallas.CityRegions.Com, October 25, 2014 ) Dallas, TX -- Researcher has released its new PharmaPoint Drug Evaluation report, “Kadcyla HER2-Positive Breast Cancer Forecast and Market Analysis to 2023″. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.
Kadcyla (ado-trastuzumab) is Roche’s third HER2-targeted mAb, approved by the FDA in February 2013, by the Japanese MHLW in September 2013, and by the EMA in November 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked to the microtubule inhibitor, DM1 (mertansine) via a non-reducible thioether linkage (MCC).
Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=232641 .
Scope
• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Kadcyla including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Kadcyla for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Kadcyla performance
• Obtain sales forecast for Kadcyla from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=232641 . (Single User License : US$ 3495 And Corporate User License : US$ 10485)
Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Basic Breast Anatomy 14
3.3 Breast Cancer Staging 15
3.4 Prognosis 16
3.5 Quality of Life 17
3.6 Symptoms 19
4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 20
4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) 21
4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 24
5 Competitive Assessment 27
5.1 Overview 27
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com
|
|
|
|